Previous 10 | Next 10 |
SAExploration Holdings (NASDAQ: SAEX ) +183% on $130M of new projects in Alaska, Canada and the Middle East. More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., The Medicines Company, Stocks on the move, Read more ...
Myovant Sciences (NYSE: MYOV ) is up 59% premarket after the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer. More news on: Myovant Sciences Ltd., Healthcare s...
Primary efficacy endpoint met with 96.7% of men achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks Achieved all six key secondary endpoints, including superiority to leuprolide acetate on rapid suppression of testosterone and prostate-spec...
Gainers: CLVS +4.4% . MYOV +3.1% . WSG +2.6% . AMC +2.1% . OKTA +1.6% . More news on: Clovis Oncology, Inc., Myovant Sciences Ltd., Wanda Sports Group Company Limited, Stocks on the move, Read more ...
Myovant Sciences (NYSE: MYOV ) will host a conference call tomorrow, November 19, at 8:30 am ET to discuss results from a Phase 3 clinical trial, HERO , evaluating oral relugolix in men with advanced prostate cancer. More news on: Myovant Sciences Ltd., AbbVie Inc., Healthcare stocks ne...
BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced it will hold a webcast and conference call beginning at 8:30 a.m. Eastern Time / 5:30...
Myovant Sciences (NYSE: MYOV ): Q3 GAAP EPS of -$0.79 misses by $0.01 . More news on: Myovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
-Landmark Agreement with Sumitomo Dainippon Pharma to provide major financial backing and safeguards for minority shareholders -Myovant to report top-line data from Phase 3 HERO study in advanced prostate cancer by the end of calendar year 2019 and Phase 3 SPIRIT studies in endomet...
Myovant Sciences ( MYOV +8.8% ) inks an agreement with Sumitomo Dainippon Pharma Co., Ltd. for a $350M low-interest five-year loan facility plus a guarantee that the Myovant board will continue to include at least three independent directors who will have approval rights over certain cor...
Sumitomo Dainippon Pharma to provide Myovant Sciences with a $350 million, low-interest, five-year term loan facility, with no repayments due until the end of the term Opportunity to access Sumitomo Dainippon Pharma’s commercial infrastructure and operational support for planned re...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...